Method for detecting a urinary tract infection (UTI) in a subject comprising determining levels of one or more biomarkers selected from MMP8, HNE, Cystatin C, MMP9, HSA, IL-8, interleukin-6 (IL-6), interleukin-1 beta (IL-1b), fibrinogen, RBP4, active MMP9 and MMP2, NGAL, Desmosine, MPO and CRP in a urine sample obtained from the subject. The determined levels may then be compared with a threshold level, wherein increased levels of at least one of the biomarkers in the urine sample relative to the threshold level is indicative of the presence of a urinary tract infection. Methods for monitoring a UTI and monitoring treatment of a UTI are also provided as are companion systems or test kits.

A method for predicting the degree of weight loss attainable by applying one or more dietary interventions to a subject, said method comprising determining the level of one or more biomarkers in one or more samples obtained from the subject, wherein the biomarkers are selected from fructosamine and factor VII.

Provided is a sample analysis method, including separating albumin and ?-globulin from a sample containing albumin and ?-globulin, in an alkaline solution by capillary electrophoresis, in which the sample contains a non-surfactant-type sulfobetaine, and the alkaline solution contains a cationic polymer.

The present invention provides a method, wherein the method classifies a subject as suffering from dry eye, the method consisting of: a. obtaining demographic data, consisting of the age and gender of the subject; b. obtaining a tear sample from the patient, and determining the level of human serum albumin; c. from the determined level of human serum albumin, assigning a score for the determined amount of human serum albumin; and d. from the assigned score, calculating a cutoff probability score, according to the following equation: wherein the subject has dry eye, if the calculated cutoff probability score is from 50% to 60%.

[00001]$\frac{\exp \left(-0.6491-1.1142*\mathrm{Albumin}\right)}{1+\exp \left(-0.6491-1.1142*\mathrm{Albumin}\right)}$

An object of the present invention is to provide a method of measuring a glycated-albumin (GA) value traceable to a certified GA value conveniently at a low cost in a short period of time. A method of measuring a GA value traceable to the certified GA value includes the following steps: A.sub.1) determining Regression equation III by steps including the following b), c), and e.sub.0) to h); b) determining a GA concentration [.sub.L] (A) of two or more GA certified reference materials having respectively different certified GA values; c) measuring a GA-derived absorbance (D) of the two or more GA certified reference materials; e.sub.0) creating Linear equation II.sub.0 having an intercept of zero; f) determining two or more GA concentrations.sub.[P] (E) proportionate to the GA-derived absorbance (D) according to Equation II.sub.0; g) determining two or more GA values (F); and h) creating Regression equation III.

Provided herein are methods for generating a solid antigen/carrier protein gel for immunohistochemistry (IHC) staining, as well as gels, kits and methods of use thereto. In particular, the methods, gels and kits provided herein include a purified antigen such as a polypeptide antigen, and a carrier protein such as a serum albumin protein, an egg white protein or mixture of egg white proteins, gelatin, or poly-lysine. Examples are provided in which the purified antigen is cross-linked to the carrier protein in the solid antigen/carrier protein gel.

The present invention relates to methods and biomarkers for detection, characterization and treatment of conditions associated with methylglyoxal (MG) in biological samples. In particular, the present invention provides compositions and methods for determining diabetic complication onset in a patient through detecting a o-phenylenediamine derivatized MG (2MQ) product as indicative of the presence of MG, impaired fibrinolysis in a patient through detecting a MG modified plasminogen (Pg) product as indicative of impaired fibrinolysis, and the efficacy of metformin (MF) treatment in a patient through detecting IMZ as indicative of a MF/MG product.

Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to human serum albumin. The FcRn-binding proteins can be used to treat a variety of disorders including acute and chronic toxic exposure.

Systems and methods are provided for predicting the likelihood of acute kidney injury. An input interface is configured to receive a plurality of features derived from the results of a post-surgical metabolic blood panel and either a pre-surgical metabolic blood panel or a perisurgical metabolic blood panel. A predictive model is configured to calculate a parameter representing a likelihood of acute kidney injury from the plurality of features. A user interface is configured to provide the calculated parameter to a user in a human comprehensible form.

The present invention relates to a method of assessing pharmacokinetic properties of a variant of human serum albumin using a non-primate animal species where the native albumin of the animal provides minimal competition for HSA binding to the FcRn receptor in said animal. In the non-primate animal species, the binding affinity of wild type HSA to the native FcRn of said animal is the same as or higher than the binding affinity of the native albumin of said animal to the native FcRn. The present invention also relate to animal models which are particularly suitable for assessing pharmacokinetics of human serum albumin variants.